Document Detail


Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
MedLine Citation:
PMID:  18035079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Improvement in adjunctive antithrombotic therapy is a key point in pharmacologic reperfusion for ST-segment elevation myocardial infarction (STEMI). The aim of the current study was to perform an updated meta-analysis of all randomized trials comparing low-molecular-weight heparins (LMWHs) versus unfractionated heparin (UFH) in patients with STEMI treated with thrombolysis. METHODS: We obtained results from all randomized trials comparing LMWHs versus UFH among patients with STEMI treated with thrombolysis. The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL) from January 1990 to June 2007. The following keywords were used: randomized trial, myocardial infarction, reperfusion, thrombolysis, duteplase, reteplase, tenecteplase, alteplase, UFH, LMWHs, dalteparin, nadroparin, enoxaparin, reviparin, parnaparin. Clinical end points assessed were mortality and reinfarction at 30-day follow-up, whereas major bleeding complications were assessed as safety end point. The relationship between mortality benefits from LMWHs and patient's risk profile was evaluated by using a weighted least-square regression in which results from each trial were weighted by the square root of the number of patients in each trial. No language restriction was applied. RESULTS: We identified a total of 8 randomized trials, including 13,940 patients randomized to LMWHs and 13,818 to UFH. Low-molecular-weight heparins were associated with a trend in reduction in mortality (6.6% vs 7.2%, odds ratio [OR] 0.92, 95% CI 0.84-1.01, P = .08, P heterogeneity [P het] = 0.7) and significant reduction in reinfarction (3.2% vs 4.8%, OR 0.65, 95% CI 0.58-0.64, P < .0001, P het = 0.39), but a higher risk of major bleeding complications (2.4% vs 1.8%, OR 1.37, 95% CI 1.16-1.61, P < .001, P het = 0.32). CONCLUSIONS: Among patients with STEMI treated with thrombolysis, LMWHs, as compared to UFH, are associated with a trend in mortality benefits and a significant reduction in reinfarction (reMI) at 30-day follow-up, but with higher risk of major bleeding complications. In view of the additional practical advantages, such as reduced interindividual variability in therapeutic response and no need for frequent activated partial thromboplastin time (aPTT) monitoring and dose adjustment, LMWHs should be considered, instead of UFH, among patients with STEMI treated with thrombolysis.
Authors:
Giuseppe De Luca; Paolo Marino
Related Documents :
8641009 - Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-...
11145489 - Novel dosing regimen of eptifibatide in planned coronary stent implantation (esprit): a...
16721199 - Which strategy should be used for acute st-elevation myocardial infarction in patients ...
18434719 - Less benefit from warfarin in diabetics after myocardial infarction?
1535419 - Do the results of randomized clinical trials of cardiovascular drugs influence medical ...
17070169 - Risks and benefits of combining aspirin with anticoagulant therapy in patients with atr...
20795939 - Vitamin d biology in heart failure: molecular mechanisms and systematic review.
12448569 - Is left ventricular hypertrophy a risk factor in hypertensive patients?
12137349 - The morphology of the specialized atrioventricular junctional area: the evolution of un...
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis     Date:  2007-10-26
Journal Detail:
Title:  American heart journal     Volume:  154     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-23     Completed Date:  2007-12-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1085.e1-6     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiology, Maggiore della Carità Hospital, Eastern Piedmont University A. Avogadro, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Drug Therapy, Combination
Fibrinolytic Agents / therapeutic use*
Heparin / therapeutic use*
Heparin, Low-Molecular-Weight / therapeutic use*
Humans
Myocardial Infarction / drug therapy*,  mortality
Thrombolytic Therapy*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial...
Next Document:  The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infe...